The FDA has approved Onapgo (apomorphine hydrochloride) for the treatment of motor fluctuations in adults with advanced Parkinson disease.

The FDA has approved Onapgo, the first subcutaneous apomorphine device to treat motor fluctuations in adults with Parkinson’s disease, according to the manufacturer.In a press release, Supernus ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo), for the treatment of adults with advanced Parkinson disease.

The FDA has approved Onapgo, a new wearable device for adults with advanced Parkinson’s disease that gives a steady dose of apomorphine under the skin to help manage movement issues and daily ...

Supernus Pharmaceuticals has won US approval for its wearable pump Onapgo (apomorphine hydrochloride) to treat symptoms of Parkinson’s disease. Supernus’ regulatory path for Onapgo has been ...

(RTTNews) - Supernus Pharmaceuticals, Inc. (SUPN), a biopharmaceutical company, announced on Tuesday the FDA approval of ONAPGO or apomorphine hydrochloride for the treatment of motor fluctuations ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease. The US FDA this week approved the sale of the treatment, which ...

Supernus Pharmaceuticals’ Onapgo provides a continuous infusion of apomorphine to manage “off” periods experienced by Parkinson’s disease patients. Approval of Onapgo comes after the FDA ...